杜瓦卢马布
医学
头颈部
肿瘤科
基底细胞
内科学
头颈部鳞状细胞癌
头颈部癌
外科
癌症
免疫疗法
无容量
作者
Robin Park,Jiannong Li,Robbert J.C. Slebos,Ritu Chaudhary,Maria I. Poole,Carina Ferraris,Joaquim Farinhas,Juan Hernandez-Prera,Kedar Kirtane,Jamie K. Teer,Xiaofei Song,MacLean S. Hall,Jason Tasoulas,Antonio L. Amelio,Christine H. Chung
出处
期刊：Oral Oncology
[Elsevier]
日期：2024-07-01
卷期号：154: 106866-106866
标识
DOI：10.1016/j.oraloncology.2024.106866
摘要
IRX-2 is a multi-cytokine immune-activating agent with anti-tumor activity in non-metastatic head and neck squamous cell carcinoma (HNSCC). Here, we evaluated combined IRX-2 and durvalumab in patients with recurrent and/or metastatic HNSCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI
杳鸢
不配.
YuanbinMao
嗯哼
乐乐乐乐乐乐
Endlessway
一一
完美的天空
8R60d8
36456657
HCLonely
xjcy
甜甜玫瑰
tuanheqi
精明的迎松
Billy
子车茗
三新荞
pluto
shinysparrow
皖公网安备34019202002308
